Automatic detection and segmentation of cerebral metastases and meningiomas

mdbrain Tumor Differentiation Update
With the latest version of mdbrain (4.11), in addition to the automatic differentiation of the tumor core and surrounding T2/FLAIR hyperintensities of glioblastomas, metastases and meningiomas are now also segmented.

Precise and comprehensive diagnostics form the basis for modern treatment of cerebral tumors. Not only the initial diagnosis, but also the follow-up plays a decisive role. With the mdbrain Tumor-Module we offer the first and so far only tool for AI-assisted evaluation of MRI images for neuro-oncological diagnosis. The results are directly integrated into the PACS as PDF reports and overlays. A direct interface to radiotherapy and neurosurgery software is also possible.

 

Precise monitoring for more and more patients 

With the first version of the tumor module, solid tumor components were already differentiated after contrast agent uptake, allowing delineation and quantification of the tumor core and surrounding T2/FLAIR hyperintensities. However, the scope of application was limited to glioblastomas until now. By including meningiomas and metastases, many more patients can benefit from mdbrain. The automatic segmentation and differentiation supplement the radiologists' assessment with an objective second opinion. Additionally, changes over time are clearly quantified through automated volume calculation (growth rate in % / year) indicative of progression. 

 

Experience the benefits of the mdbrain Tumor Module live

For all interested parties, we offer a free and non-binding product demo conducted via video call by our product specialist and radiological expert, Marco Le Donne. Subsequently, an uncomplicated and free test via our browser-based Online-Demo is possible. Do not hesitate and book an appointment with us today.

Solutions

mediaire GmbH

Möckernstrasse 63
10965 Berlin, Germany

P +49 30 286 490 67
F +49 30 286 490 66

© 2025 mediaire GmbH

WORLD PREMIERE AT THE RÖKO 2024 IN GERMANY

Experience mdprostate, the first fully-automated AI-tool including longitudinal assessment for the evaluation of prostate MRIs.

mediaire GmbH

Möckernstrasse 63
10965 Berlin, Germany

P +49 30 286 490 67
F +49 30 286 490 66

© 2022 mediaire GmbH